ENTITY
Shanghai Junshi Biosciences

Shanghai Junshi Biosciences (1877 HK)

220
Analysis
Health CareChina
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
bullishRemegen
15 Mar 2021 09:12

Remegen Co Ltd (9995.HK) - Commercialized RC18 + IPO On SSE STAR Market = New Chapter & Challenges

The article analyzed RemeGen's first commericalized product RC18, the challenges in R&D failure, fierce competition, commercialization and...

Logo
263 Views
Share
14 Mar 2021 13:12

Quiddity Weekly H/A: Energy Up, Spreads Wider, Pharmas Down Spreads Narrower

Spread momentum continues unabated. Of note, CanSino's vaccine approval is getting no friends as the stock is down nearly 25% in 2 weeks and 29% in...

Logo
184 Views
Share
14 Mar 2021 09:07

China Healthcare Weekly (Mar.12)

The article analyzed viewpoints of potential VBP on insulin, internationalization of domestic pharmaceutical companies, commercial health...

Logo
238 Views
Share
11 Mar 2021 09:37

Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%

This article analyzed the concerns of Genor Biopharma in terms of core products, competitive landscape, industry characteristics and the potential...

Logo
298 Views
Share
07 Mar 2021 21:42

Quiddity Weekly H/A: Financials Outpace Everything Else: Marketwide 87% Upside to A-Share Parity

H/A spreads were largely unchanged on the week but more widened than narrowed. Financials was the only sector narrower on the whole. With average...

Logo
231 Views
Share
x